In the literature, we found that modified B2M had been shown in the serum of patients suffering of small cell lung cancer35, AIDS, chronic haemodialysis36, the synovial fluids of patients with rheumatoid arthritis37 and the urine of patient with acute tubular injury of renal allografts38 as well as healthy individuals39, suggesting a proteolytic process involved the cleavages of native B2M. This evidence concerns the gene B2M and AIDS.